Insurance Coverage: Many major insurance plans no longer cover Byetta as of 2015. Learn More
Dr. Sharon Orrange - October 06, 2015
More than 29 million Americans have diabetes. That’s more than 10% of the US—and that number continues to rise. More than 1.7 million adults were diagnosed with diabetes in 2012 alone.
Fortunately, several new medications for diabetes have recently been approved—Toujeo (a new insulin product), Synjardy (a new combination of empagliflozin/metformin) and others. These new drugs provide several benefits such as fewer side effects or foolproof self-dosing with an insulin pen. See More
The GoodRx Pharmacist - May 05, 2015
Did you read our blog on insulin vials and think to yourself, does this apply to my insulin pens too? If so, this post is for you!
With so many different insulin and insulin-like products out there these days it can be hard keep track of how long each of these pens stays good.
Depending on your dose, you may still have insulin left in your pen at the manufacturer-recommended time to throw it away. If this sounds like a familiar situation, know that it is important to throw away your pen regardless of whether you have any leftover. See More
The GoodRx Pharmacist - November 10, 2014
The FDA recently approved a new PEN form of diabetes injection Bydureon (exenatide), which is gaining popularity and causing mix-ups at the pharmacy.
The existing Bydureon vial and the new pen contain the same medication, but the two forms are not interchangeable—your pharmacist will need to fill the form your doctor has prescribed.
Dr. Sharon Orrange - November 04, 2014
The newest of the injectable diabetes medications which also helped diabetics lose weight is Trulicity, just approved in September 2014. Given that Trulicity has a low incidence of hypoglycemia and mild gastrointestinal side effects it will become a good option for type II diabetics.
The GoodRx Pharmacist - September 26, 2014
Trulicity (dulaglutide) is a new once-weekly injection approved for the treatment of type 2 diabetes, in combination with diet and exercise. It was approved by the FDA on September 18, 2014.
When will Trulicity be available?
According to the manufacturer, Eli Lilly and Company, the anticipated availability date for Trulicity is later this year.
The GoodRx Pharmacist - September 15, 2014
As 2014 comes to a close, we should be thinking about what to expect for 2015. The start of a new year is a time for new challenges, new goals, and inevitably, a new prescription formulary.
What does this mean for you?
Express Scripts and Caremark have decided to remove certain diabetes medications from their national preferred formulary and provided a list of covered alternatives. For more information and the full list of excluded drugs, see our post on the 2015 formulary changes. See More
Elizabeth Davis - August 20, 2014
For many Americans with health insurance, more than 40 popular brand-name drugs may no longer be covered starting in January 2015. Express Scripts and Caremark, companies that handle pharmacy benefits for more than 200 million Americans, are removing over 40 drugs from their formularies at the end of 2014. This is in addition to the more than 50 drugs removed last year.
What are Express Scripts and Caremark?
Express Scripts and Caremark are companies that administer prescription drug benefits for many health insurance companies and Tricare. See More
The GoodRx Pharmacist - July 28, 2014
Byetta (exenatide) and Bydureon (exenatide) for type 2 diabetes can be confusing—they have similar names, and both are injected rather than taken orally. However, there are advantages and disadvantages to each, and they are available in different strengths, and have different directions for use.
What is type 2 diabetes?
Type 2 diabetes, also known as adult onset diabetes, occurs when the body does not use the insulin it makes properly. See More
The GoodRx Pharmacist - April 28, 2014
Tanzeum (albiglutide) has just been approved by the FDA for the treatment of type 2 diabetes. It is intended to be used in combination with diet and exercise to help improve your blood sugar.
Dr. Sharon Orrange - January 03, 2014
Incretin based therapy is the broad term that includes our new GLP-1 receptor agonists. It’s a mouthful, but they are the new heroes in the treatment of type II diabetes given their effectiveness and ability to help you lose weight.
GLP-1 receptor agonists are all injections which differ in how often you give them. They all may cause nausea which thankfully tends to diminish over time. They potentially carry a very small risk of pancreatitis, which is difficult to sort out because the risk of pancreatitis is higher in type II diabetics anyway. See More